They sue me because the medicine is illegal, but if it is legal, they say I can't afford it?

Chapter 242 2 million.

……

“I don’t plan to sell the formula though.”

"But I'm also very pragmatic. As long as the offer is high enough, I can change my mind."

"Of course, if it's a normal price, then please don't ask Mr. Gao."

After Gao Tianlong finished speaking, Chen Xuan also expressed his opinion.

He really didn't want to sell the formula for the lung cancer drug.

But at the same time, if the other party's price is really so high that he can't refuse it, it's not impossible to agree.

For example, if the profits from selling to AbbVie are greater than developing and selling it by himself, then he can sell it directly.

There is nothing that cannot be cooperated with, and there is no product that cannot be sold. As long as it is a product, it has a certain price. It just depends on whether the buyer can offer this price.

He also expressed this very clearly.

But at the same time, this also means to remind Gao Tianlong that if the price is not high enough, don't waste time.

"Mr. Chen, don't worry about the price. Our offer will definitely satisfy you."

"Twenty billion. We at AbbVie plan to spend twenty billion to acquire the complete formula."

"From now on, the global intellectual property rights of this drug will belong to AbbVie, which is equivalent to a one-time buyout."

"Mr. Chen, we are very sincere in cooperating with you, so our offer is also very sincere."

Gao Tianlong said confidently that he believed this price was enough to impress Chen Xuan.

After all, 200 billion for one drug formula.

Whether this can be considered unprecedented is hard to say.

But a drug formula that has not yet completed clinical trials can be sold for 200 billion. This is the first time in history.

Therefore, he was confident that he could impress Chen Xuan, and the latter would definitely agree to this condition.

AbbVie originally did not intend to bid 200 billion at once, as they believed that clinical trials still had certain risks.

But after Changfeng Group made its bid, AbbVie immediately changed its mind, and Gao Tianlong's reserve price was much higher.

This move is worth 200 billion, and a big reason for this is the influence brought by Changfeng Group.

"Besides, if Mr. Chen is willing,"

"We can also acquire 60% of Antai Pharmaceutical Group's shares for 120 billion yuan."

"We at AbbVie are very interested in both you and Antai Pharmaceutical Group, and hope to maintain long-term cooperation with you. With AbbVie's support, you will surely achieve even greater success in drug development."

Before Chen Xuan started, Gao Tianlong spoke again.

It sounds like AbbVie only spent 120 billion to acquire shares, which seems to be no different from Changfeng Group.

But the difference is that Changfeng Group's 120 billion yuan directly includes the formula of the special medicine for lung cancer, which is why the total valuation is 120 billion yuan.

AbbVie's 120 billion yuan was for the acquisition of additional shares after acquiring the new drug formula. It seems the same, but there is a huge difference between the before and after.

The difference is that Changfeng Group's plan allows Chen Xuan to retain 40% of the new drug patents, while Abovie's acquisition plan means that the new drug has nothing to do with him, but he can directly get an additional 20 billion yuan in cash.

In total, they could have earned 320 billion yuan, but the price they paid was losing the patent for the new drug and 60% of the group's shares.

Relatively speaking, AbbVie's bid is very generous, a real big deal.

"I feel your company's sincerity, and the conditions are indeed good."

"But... I'm sorry, I really don't intend to sell the formula."

Chen Xuan refused bluntly.

He will not sell the formula for the lung cancer drug, nor will he sell his shares in Antai Pharmaceutical Group.

Once he sells 60% of his shares, Antai Pharmaceutical Group will no longer belong to him.

According to the usual practice of foreign companies, all the advantages of Chinese companies will be eliminated, and finally they will become empty shells and destroy a brand directly.

This is especially true for corporate acquisitions within the same industry. Few Chinese brands can continue to perform better after being acquired, and most of them decline rapidly after being acquired.

They would rather lose money than suppress China's development.

The same goes for Antai Pharmaceutical Group. After being acquired by Abovie, it will definitely not develop with all its heart. Instead, Antai Pharmaceutical Group will continue to transfer profits to Abovie, and eventually be sucked dry.

So, how could Chen Xuan possibly sell his shares, let alone sell 60% at once?

Once he loses his status as a major shareholder, the future development of Antai Pharmaceutical Group will no longer be in his hands.

Moreover, there is a high possibility that he will be kidnapped by the Antai Group, and in the end he will have no choice but to work for AbbVie and contribute to it, and lose his freedom.

"Mr. Chen, our offer is very sincere."

"If our expectations are met, your company's new drug will have a very good future."

"But this is only the first phase of clinical trials, and the risk of failure is still very high. Our acquisition of patents is also a gamble on the future. If it fails, we will lose everything."

Gao Tianlong immediately said, "Under the circumstances, our bid is already very sincere. I believe it will be difficult for your company to find a buyer who can offer higher than ours."

Gao Tianlong was a little dumbfounded by Chen Xuan’s refusal.

It was such a sincere and high price, which could be called a high price to buy, so why did you refuse it without even a moment of hesitation?

You know, 320 billion yuan is more than enough to acquire a medium-sized pharmaceutical company.

Antai Pharmaceutical Group is just a newly established pharmaceutical company, and it actually refused to agree to such a sky-high acquisition.

This really made him a little confused.

"That's what AbbVie thinks, but I don't think so."

"If a new drug hasn't started clinical trials yet, that's fine."

"In fact, clinical trials for new drugs have been going on for some time now, and I'm sure you're all familiar with the daily data."

Chen Xuan shook his head and said, "From the current reports, the success rate of new drugs being approved for marketing is very high, and almost all of them are performing better than expected."

The meaning of this statement is also a direct rebuttal to Gao Tianlong.

The lung cancer drug he mentioned is still in clinical trials and the failure rate remains high, which makes the acquisition very risky.

But in fact, the lung cancer specific drug has shown very good performance in various data during clinical trials.

The volunteers' condition was also better than expected, and they showed no adverse reactions.

Judging from these data, the success rate of lung cancer-specific drugs is already very high, and the chance of failure is very small.

AbbVie also treats its lung cancer-specific drug as an ordinary drug, and includes the risks of other drugs in it, which is a bit self-deception.

Gao Tianlong...

Faced with these remarks, he could not help but remain silent.

In fact, he also knew that what Chen Xuan said made sense. Abovit analyzed various data.

The conclusion is that the success rate of lung cancer-specific drugs is very high, with a probability of passing clinical trials of over 90%.

Given the indications and therapeutic effects of this drug, once it is launched on the market, it is very likely to become the new king of medicine and be crowned as a sales myth for many years. This is why AbbVie decided to acquire it.

It is because the lung cancer drug has great potential that they offered a price of 200 billion yuan.

It was obvious that Chen Xuan also knew this, and the price alone was not enough to impress him.

……